Fibroblast Growth Factor 23 and Adverse Clinical Outcomes in Type 2 Diabetes: a Bitter-Sweet Symphony

por Yeung, Stanley M. H., Bakker, Stephan J. L., Laverman, Gozewijn D., De Borst, Martin H.
Publicado 2020

Phosphate and fibroblast growth factor 23 in diabetes

por van der Vaart, Amarens, Yeung, Stanley M.H., van Dijk, Peter R., Bakker, Stephan J.L., de Borst, Martin H.
Publicado 2021

Urinary Potassium Excretion, Fibroblast Growth Factor 23, and Incident Hypertension in the General Population-Based PREVEND Cohort

por Yeung, Stanley M. H., Hoorn, Ewout J., Rotmans, Joris I., Gansevoort, Ron T., Bakker, Stephan J. L., Vogt, Liffert, de Borst, Martin H.
Publicado 2021

Urinary potassium excretion and mortality risk in community-dwelling individuals with and without obesity

por Yeung, Stanley M H, Nooteboom, Anne, Hoorn, Ewout J, Rotmans, Joris I, Vogt, Liffert, de Boer, Rudolf A, Gansevoort, Ron T, Navis, Gerjan, Bakker, Stephan J L, De Borst, Martin H
Publicado 2022

Fibroblast Growth Factor 23 and Risk of New Onset Heart Failure With Preserved or Reduced Ejection Fraction: The PREVEND Study

por Binnenmars, S. Heleen, Hoogslag, Georgette E., Yeung, Stanley M. H., Brouwers, Frank P., Bakker, Stephan J. L., van Gilst, Wiek H., Gansevoort, Ron T., Navis, Gerjan, Voors, Adriaan A., de Borst, Martin H.
Publicado 2022

Effects of Potassium or Sodium Supplementation on Mineral Homeostasis: A Controlled Dietary Intervention Study

por Humalda, Jelmer K, Yeung, Stanley M H, Geleijnse, Johanna M, Gijsbers, Lieke, Riphagen, Ineke J, Hoorn, Ewout J, Rotmans, Joris I, Vogt, Liffert, Navis, Gerjan, Bakker, Stephan J L, de Borst, Martin H
Publicado 2020